

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 64195

**Title:** Surveillance for Hepatocellular Carcinoma in Chronic Viral Hepatitis: Is It Time to Personalize It?

**Reviewer's code:** 03537165

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Croatia

**Author's Country/Territory:** Turkey

**Manuscript submission date:** 2021-02-11

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-03-10 13:38

**Reviewer performed review:** 2021-03-21 20:50

**Review time:** 11 Days and 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

This work represents an excellent review paper on currently available HCC surveillance tools in patients with chronic liver disease. The authors mainly direct attention at the surveillance tools in patients with chronic HBV and HCV infection. I would like to ask the authors to comment the position of HCC surveillance tools in patients with non-alcoholic fatty liver disease (NAFLD), especially given the significant risk of HCC in patients without liver cirrhosis. The title, abstract, manuscript organization and presentation, discussion, tables and references are appropriate, language clear and understandable.